May 16 (Reuters) - Zymeworks Inc:
* ZYMEWORKS AND GSK EXPAND 2016 AZYMETRIC™ BISPECIFIC AGREEMENT
* ZYMEWORKS INC - IF ALL SIX PROGRAMS ARE DEVELOPED AND COMMERCIALIZED, THE NEW POTENTIAL VALUE OF THE COLLABORATION WOULD BE UP TO US$1.1 BILLION.
* ZYMEWORKS INC - ZYMEWORKS IS ELIGIBLE TO RECEIVE INCREASED TIERED ROYALTIES ON WORLDWIDE SALES
* ZYMEWORKS INC - ZYMEWORKS IS ELIGIBLE TO RECEIVE INCREASED TIERED ROYALTIES ON WORLDWIDE SALES.
* ZYMEWORKS INC - GSK WILL NOW HAVE OPTION TO DEVELOP AND COMMERCIALIZE BISPECIFIC DRUGS ACROSS DIFFERENT DISEASE AREAS
* ZYMEWORKS INC - GSK WILL HAVE ACCESS TO ZYMEWORKS' HEAVY-LIGHT CHAIN PAIRING TECHNOLOGY, PART OF ITS PROPRIETARY AZYMETRIC PLATFORM
* ZYMEWORKS INC - ZYMEWORKS WILL NOW BE ELIGIBLE TO RECEIVE INCREASED PRECLINICAL, DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS.